Burak Yıldız, Özge Keniş-Coşkun, Tuğçe Kızıltepe, Evrim Karadağ-Saygı, Pınar Ergenekon, Ela Erdem-Eralp, Yasemin Gökdemir, Bülent Karadağ
{"title":"The Validity and Reliability of the Turkish Version of the AWESCORE Test.","authors":"Burak Yıldız, Özge Keniş-Coşkun, Tuğçe Kızıltepe, Evrim Karadağ-Saygı, Pınar Ergenekon, Ela Erdem-Eralp, Yasemin Gökdemir, Bülent Karadağ","doi":"10.5152/TurkArchPediatr.2025.24199","DOIUrl":null,"url":null,"abstract":"<p><p>Objective: Patient-reported quality of life (QoL) measurement is crucial in making clinical decisions in unison with the patients. The current gold standard for cystic fibrosis (CF) is the Cystic Fibrosis Questionnaire-Revised (CFQ-R), which has different applications for different age groups and requires a computer program to be evaluated. There is a need for a straightforward way to evaluate QoL in both pediatric and adult patients with CF. The study aims to establish the validity and reliability of the Turkish version of the Alfred Wellness Score (AWESCORE) test that has been developed to evaluate QoL in patients with CF. Materials and Methods: This study is a methodological study. The AWESCORE form was translated into Turkish and was applied to patients above 10 years of age. It includes 10 questions. Each question was scored using a numerical rating scale of 0-10. Total scores ranged from 0 to 100. Test-retest reliability was assessed over 24 hours. To determine validity, comparisons were sought between stable subjects and those in pulmonary exacerbation, and between AWESCORE and CFQ-R. Results: A total of 99 patients were included, 29 of whom were during their acute exacerbation period (29%). All questions showed intraclass correlation coefficient (ICC) values above 0.9, indicating excellent reliability. Scores were higher during clinical stability compared to pulmonary exacerbation (mean ± SD): 79.35 ± 6.51 versus 41.93 ± 8.58 (P < .001). All questions were significantly worse in the acute exacerbation period, showing excellent validity with P values below .001 for each question. Conclusion: The Turkish version of the AWESCORE is valid and reliable in its ability to evaluate QoL in patients with CF.</p>","PeriodicalId":75267,"journal":{"name":"Turkish archives of pediatrics","volume":"60 2","pages":"147-152"},"PeriodicalIF":1.3000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963329/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish archives of pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/TurkArchPediatr.2025.24199","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Patient-reported quality of life (QoL) measurement is crucial in making clinical decisions in unison with the patients. The current gold standard for cystic fibrosis (CF) is the Cystic Fibrosis Questionnaire-Revised (CFQ-R), which has different applications for different age groups and requires a computer program to be evaluated. There is a need for a straightforward way to evaluate QoL in both pediatric and adult patients with CF. The study aims to establish the validity and reliability of the Turkish version of the Alfred Wellness Score (AWESCORE) test that has been developed to evaluate QoL in patients with CF. Materials and Methods: This study is a methodological study. The AWESCORE form was translated into Turkish and was applied to patients above 10 years of age. It includes 10 questions. Each question was scored using a numerical rating scale of 0-10. Total scores ranged from 0 to 100. Test-retest reliability was assessed over 24 hours. To determine validity, comparisons were sought between stable subjects and those in pulmonary exacerbation, and between AWESCORE and CFQ-R. Results: A total of 99 patients were included, 29 of whom were during their acute exacerbation period (29%). All questions showed intraclass correlation coefficient (ICC) values above 0.9, indicating excellent reliability. Scores were higher during clinical stability compared to pulmonary exacerbation (mean ± SD): 79.35 ± 6.51 versus 41.93 ± 8.58 (P < .001). All questions were significantly worse in the acute exacerbation period, showing excellent validity with P values below .001 for each question. Conclusion: The Turkish version of the AWESCORE is valid and reliable in its ability to evaluate QoL in patients with CF.